To answer a question I had about retreatment (maybe others already were comfortable with a treat once only), on the Barclay's call BMRN was asked about the possibility (what type of efficacy needed) and they said that typically its not possible to retreat because the patient gets an immune response. I wonder if any of the other companies are looking at ways to get around the immune response should the treatment be efficacious just not curative?
Market Data 
Markets 
AI
